Blueprint Medicines Corporation

This study is for people with systemic mastocytosis who have already been taking avapritinib and benefiting from it. Researchers want to see how safe the drug is over a longer period of time by tracking serious side effects. About 60 participants will continue their treatment and…

This study follows about 80 people in Germany who have indolent systemic mastocytosis (ISM) and are starting avapritinib as part of their normal care because other treatments haven't controlled their symptoms well enough. Researchers will track changes in quality of life and othe…

This study tests a new drug called elenestinib (BLU-263) for people with indolent systemic mastocytosis whose symptoms are not well controlled by current treatments. About 534 adults will receive either the drug or a placebo alongside their usual symptom-relief medications. The g…

This study tests an experimental drug called BLU-808 for people with chronic hives (either triggered by heat, cold, or pressure, or happening for no clear reason) that don't get better with standard allergy pills. The goal is to see if the drug is safe and can reduce hives sympto…

This study watches 150 adults with indolent systemic mastocytosis (ISM) to see how the disease affects them over time. Researchers will collect information on symptoms, treatments, and quality of life through questionnaires and lab tests. No new treatment is given; the goal is to…

This study aims to find out how often a specific genetic change, called KIT D816V, occurs in people who may have clonal mast cell disease. About 450 participants will provide blood samples, which will be tested using two advanced methods. The results will help researchers better …